Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

233 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and pharmacokinetics of oral and long-acting injectable cabotegravir or long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study.
Gaur AH, Capparelli EV, Calabrese K, Baltrusaitis K, Marzinke MA, McCoig C, Van Solingen-Ristea RM, Mathiba SR, Adeyeye A, Moye JH, Heckman B, Lowenthal ED, Ward S, Milligan R, Samson P, Best BM, Harrington CM, Ford SL, Huang J, Crauwels H, Vandermeulen K, Agwu AL, Smith-Anderson C, Camacho-Gonzalez A, Ounchanum P, Kneebone JL, Townley E, Bolton Moore C; IMPAACT 2017 Collaborators; IMPAACT 2017 Team. Gaur AH, et al. Among authors: milligan r. Lancet HIV. 2024 Apr;11(4):e211-e221. doi: 10.1016/S2352-3018(23)00300-4. Lancet HIV. 2024. PMID: 38538160 Clinical Trial.
Acceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAACT 2017/MOCHA): a secondary analysis of a phase 1/2, multicentre, open-label, non-comparative dose-finding study.
Lowenthal ED, Chapman J, Ohrenschall R, Calabrese K, Baltrusaitis K, Heckman B, Yin DE, Agwu AL, Harrington C, Van Solingen-Ristea RM, McCoig CC, Adeyeye A, Kneebone J, Chounta V, Smith-Anderson C, Camacho-Gonzalez A, D'Angelo J, Bearden A, Crauwels H, Huang J, Buisson S, Milligan R, Ward S, Bolton-Moore C, Gaur AH; IMPAACT 2017 Collaborators; IMPAACT 2017 Team. Lowenthal ED, et al. Among authors: milligan r. Lancet HIV. 2024 Apr;11(4):e222-e232. doi: 10.1016/S2352-3018(23)00301-6. Lancet HIV. 2024. PMID: 38538161 Clinical Trial.
Wire- and radiofrequency identification tag-guided localization of impalpable breast lesions: iBRA-NET localization study.
Harvey J, Morgan J, Lowes S, Milligan R, Barrett E, Carmichael A, Elgammal S, Masudi T, Holcombe C, Masannat Y, Potter S, Dave RV; iBRA-Net Localization Study Collaborative. Harvey J, et al. Among authors: milligan r. Br J Surg. 2024 Jan 31;111(2):znae007. doi: 10.1093/bjs/znae007. Br J Surg. 2024. PMID: 38326941 No abstract available.
Dental screening: pre-cardiac surgery.
Milligan R, Ramadan M, Stewart V, Beresford A, Marley J, Elsherif N. Milligan R, et al. Br Dent J. 2023 Dec;235(11):843. doi: 10.1038/s41415-023-6619-6. Epub 2023 Dec 8. Br Dent J. 2023. PMID: 38066122 No abstract available.
The SARS-CoV-2 protein ORF3c is a mitochondrial modulator of innate immunity.
Stewart H, Lu Y, O'Keefe S, Valpadashi A, Cruz-Zaragoza LD, Michel HA, Nguyen SK, Carnell GW, Lukhovitskaya N, Milligan R, Adewusi Y, Jungreis I, Lulla V, Matthews DA, High S, Rehling P, Emmott E, Heeney JL, Davidson AD, Edgar JR, Smith GL, Firth AE. Stewart H, et al. Among authors: milligan r. iScience. 2023 Sep 28;26(11):108080. doi: 10.1016/j.isci.2023.108080. eCollection 2023 Nov 17. iScience. 2023. PMID: 37860693 Free PMC article.
233 results